|Glaucoma remains a serious threat to vision, despite various treatment options. Advances in the understanding of aqueous humor outflow mechanisms have contributed to the development of more effective techniques for the management of intraocular pressure (IOP), but controversies remain. A growing number of procedures that avoid conjunctival dissection, collectively termed minimally invasive glaucoma surgery (MIGS), offer alternatives to trabeculectomy for patients who would benefit from IOP lowering beyond what medications alone can offer. In addition, despite the effectiveness of available antiglaucoma agents, adherence continues to be problematic. Sustained-release platforms for antiglaucoma medications may address this challenge. In this CME activity, experts in the field explore the sustained-release formulations of antiglaucoma medications that can improve patient adherence—as well as newer MIGS procedures and technology that can optimize outcomes.